Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation with regard to its accuracy or completeness, and expressly disclaim any liability for any loss whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



杭州啓明醫療器械股份有限公司

Venus Medtech (Hangzhou) Inc.

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2500)

COMPLETION OF THE CONVERSION AND LISTING OF UNLISTED DOMESTIC SHARES

Reference is made to the announcements (the "**Announcements**") of Venus Medtech (Hangzhou) Inc. (the "**Company**") dated June 15, 2020, June 22, 2020, August 14, 2020, November 23, 2020 and November 27, 2020 in relation to the H share full circulation programme of the Company, under which (i) the Company is allowed to convert an aggregate of 221,752,871 unlisted domestic shares into overseas-listed shares of the Company (the "**H Shares**") and their listing on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") was approved; and (ii) the conversion of 212,450,085 Unlisted and Unpledged Domestic Shares into H Shares was completed on November 27, 2020 and the listing of such portion of Converted H Shares on the Stock Exchange commenced at 9:00 a.m. on November 30, 2020. Unless otherwise indicated, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

COMPLETION OF THE CONVERSION AND LISTING OF THE UNLISTED AND PLEDGED DOMESTIC SHARES

The board of directors of the Company (the "**Board**") is pleased to announce that after release of the pledge of the 9,302,786 unlisted and pledged domestic shares (the "**Relevant Unlisted Domestic Shares**") and with the authorisation and on behalf of the holders of the Relevant Unlisted Domestic Shares, on July 2, 2021, the Company completed the cancellation registration procedure for the Relevant Unlisted Domestic Shares (the "**China Clearing**"), Beijing Branch and the name of the shareholder holding the Relevant Unlisted Domestic Shares has been removed from the register of members of Unlisted Domestic Shares maintained by China Clearing. The conversion of the Relevant Unlisted Domestic Shares into H Shares (the "**Converted H Shares**") was completed on July 20, 2021 and the listing of such portion of Converted H Shares on the Stock Exchange will commence at 9:00 a.m. on July 21, 2021.

The holder of the Converted H Shares who are PRC nationals can only conduct trading of the Converted H Shares subject to the completion of the onshore arrangement procedures as set out in the announcement of the Company dated November 23, 2020.

SHARE CAPITAL STRUCTURE

Upon completion of the conversion and listing of the Relevant Unlisted Domestic Shares, the share capital structure of the Company is set out below:

Class of shares	Immediately before completion of the conversion and listing of the Relevant Unlisted Domestic Shares		Upon completion of the conversion and listing of the Relevant Unlisted Domestic Shares	
	Number of	Percentage	Number of	Percentage
	Shares	(approximately)	Shares	(approximately)
Unlisted Domestic Shares	9,303,994	2.11%	1,208	0.00%
H Shares	431,707,449	97.89%	441,010,235	
Total number of issued Shares	441,011,443	100.00%	441,011,443	100.00%

Note: The percentages have been rounded off to two decimal places.

By order of the Board Venus Medtech (Hangzhou) Inc. Min Frank Zeng Chairman

Hangzhou, July 20, 2021

As at the date of this announcement, the executive Directors are Mr. Min Frank Zeng, Mr. Zhenjun Zi and Mr. Lim Hou-Sen (Lin Haosheng); the non-executive Director is Ms. Nisa Bernice Wing-Yu Leung; and the independent non-executive Directors are Mr. Ting Yuk Anthony Wu, Mr. Wan Yee Joseph Lau and Mr. Chi Wai Suen.